NSC |
Compound |
Enrichment |
Correlation |
NSC 668296 |
Null |
0.0179905510964915 |
0.39298935 |
NSC 668494 |
Null |
0.0179905510964915 |
0.40188865 |
NSC 67588 |
2-Naphthacenecarboxamide, 4-dimethylamino-1,4,4a,5,5a,6,11,12a-pentahydroxy-N-[6-mercaptopurin-7(or 9)-ylmethyl]-6-methyl-1,11-dioxo- |
0.0179905510964915 |
0.22367496 |
NSC 686557 |
Null |
0.0179905510964915 |
0.38522015 |
NSC 709974 |
Null |
0.0186186224062458 |
0.35914598 |
NSC 715407 |
Null |
0.0186186224062458 |
0.43375575 |
NSC 718781 |
Erlotinib hydrochloride |
0.0186186224062458 |
-0.22415134 |
NSC 719667 |
7-methoxy-8-[3-(1,4-oxazinan-4-yl)propoxy-(11aS)-2,3,5,11a -tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one |
0.0186186224062458 |
0.37048954 |
NSC 720320 |
1,6-bis-(2,6-difluorobenzyl)-2-(2,6-difluorophenyl)-5-methoxy-benzimidazole |
0.0186186224062458 |
0.046549034 |
NSC 724783 |
[1,5-dimethyl-10-(trifluoromethyl)-11,14,15,16-tetraoxatetra cyclo[10.3.1.04,13.08,13]hexadec-9-en-9-yl]-N,N-bis{[1,5-dim ethyl-10-(trifluoromethyl)-11,14,15,16-tetraoxatetracyclo[10 .3.1.04,13.08,13 |
0.0186186224062458 |
0.23653361 |